Please login to the form below

Not currently logged in
Email:
Password:

Ramprasad Reddy to chair Aurobindo’s US business

Will also step down from position as full-time director

P V Ramprasad Reddy, who resigned as executive chair of the board of Indian firm Aurobindo in June, 2012, has been appointed chair of its US subsidiary, Aurobindo Pharma USA.

The decision was approved by Aurobindo's board of directors in a meeting last week, although the proposal is still subject to further approval from shareholders, with an extraordinary general meeting scheduled for September 27, 2012 to confirm the appointment.

If approved, Ramprasad Reddy will assume his new position on December 1, 2012.

In addition, Aurobindo's board also approved that Ramprasad Reddy relinquish his executive responsibilities as full-time director of the company, although he will continue as non-exectuive director.

Ramprasad Reddy also has roles at several other Aurobindo subsidiaries, which include serving as director of APL Pharma Thai Limited, Aurobindo (Datong) Bio-Pharma and Aurobindo Tongling (Datong) Pharmaceutical.

In 2008, World Pharmaceutical Frontiers named Ramprasad Reddy as one of the 35 most influential people in the pharmaceutical industry.

29th August 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Indigenus

Indigenus is the largest global network of independent healthwellness communication companies, delivering a full-service menu of strategic, creative, and digital...

Latest intelligence

BL_Where_Now_20140721_CoverImage.jpg
3 Steps to Navigating Multichannel in Healthcare
You know about multichannel, but... where now? Download the 3 Steps to Navigating Multichannel in Healthcare ebook to learn what you should do next when planning your multichannel campaign....
Online Physician Communities
How can pharma develop a more customer-centric approach?
Business pressures and customer needs will force pharma to focus on multichannel marketing in the next few years...
Exploring MINT: Part 2 - Indonesia
In the second of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Indonesia, with...